Lilly probably has little incentive to pair eloralintide with retatrutide. A 3 mg eloralintide plus 5 mg tirzepatide regimen already delivered 17 percent weight loss in 16 weeks, which beats retatrutide results so far. They risk cutting into sales of their existing drugs, so the more likely approach is marketing eloralintide with tirzepatide for plateaus and non-responders rather than launching a standalone combo that would rival retatrutide.
A new paper in Nature reports that adding cagrilintide to retatrutide produced greater weight reduction and better metabolic markers in obese male rats than retatrutide by itself or similar combinations with semaglutide or tirzepatide. The outcome lines up with what people have already seen in practice, so it backs the idea that retatrutide users might gain from adding cagrilintide or eloralintide. It would be useful to see how the combo stacks up against a modestly higher retatrutide dose alone.